搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按时间排序
按相关度排序
Targeted Oncology
1 小时
Tamoxifen Cuts 15-Year Recurrence in DCIS Without Radiation Therapy
An analysis of phase 3 trials found tamoxifen significantly reduced 15-year ipsilateral breast recurrence in patients with ...
Targeted Oncology
1 小时
Effective and Well-Tolerated Combo in ER+/HER2– Metastatic Breast Cancer
Hope S. Rugo, MD, FASCO, discusses how the combination of elacestrant and abemaciclib compares with other treatment options for patients with advanced breast cancer, whether estrogen receptor-positive ...
Targeted Oncology
2 小时
Luspatercept and ESAs Improve Efficacy in VEXAS Syndrome With/Without MDS
Erythropoietin stimulating agents and/or luspatercept showed positive clinical efficacy and safety in patients with VEXAS ...
Targeted Oncology
18 小时
Navtemadlin Monotherapy Shows Safety, Efficacy in R/R Myelofibrosis
Findings from the BOREAS study showed that navtemadlin as a monotherapy led to safety and efficacy in patients with ...
Targeted Oncology
21 小时
Palbociclib Combo Shows Benefit to PFS in HR+, HER2+ Breast Cancer
Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic ...
Targeted Oncology
23 小时
Kaklamani on Elacestrant for CDK4/6 Inhibitor-Naive ER+ Breast Cancer Treatment
Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen ...
Targeted Oncology
1 天
Brexu-cel Shows Comparable Efficacy in Patients With B-ALL Aged 60-69
Brexucabtagene autoleucel showed comparable efficacy outcomes in patients aged 60 to 69 with relapsed/refractory B-cell acute ...
Targeted Oncology
1 天
Lower Cardiac Risks Found With Second-Generation BTK Inhibitors in B-Cell Hematologic Disorders
In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, ...
Targeted Oncology
1 天
No OS Difference Among First-Line CDK4/6 Inhibitors in HR+/HER2- mBC
A study of 9,146 patients found no OS difference among first-line CDK4/6 inhibitor combinations for HR+/HER2- metastatic ...
Targeted Oncology
1 天
Dealing With Transfusion Dependence in Patients With MDS
Abdulraheem Yacoub, MD, discusses option for patients with myelodysplastic syndromes and red blood cell transfusion dependence.
Targeted Oncology
1 天
Ten-Year Retrospective Trial of Ponatinib in Leukemia Sheds Light on AE Mitigation Efforts
Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, ...
Targeted Oncology
1 天
Phase 2 Trial Highlights 100% Complete Response with Cilta-Cel in Smoldering Myeloma
Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈